A New Drug for Psoriasis
A drug for treatment of active psoriatic arthritis and plaque psoriasis of medium and high severity in adult patients has been launched in Russia.
The new drug is a phosphodiesterase 4 (PDE4) inhibitor, INN Apremilast. It has selective balanced effects on inflammation factors in patients with psoriatic skin and locomotor lesions. Effects and safety of the new drug has been evidenced in double-blind randomized placebo-controlled clinical trials ESTEEM involving patients with medium and high severity psoriasis.
Three-year clinical trial program PALACE 1-3, involving patients with active psoriatic arthritis also showed safety and efficacy of the new substance.
The drug is authorized for marketing in the territory of the Russian Federation. Marketing Authorization Certificate No is ЛП-003819 of 05.09.2016.